Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 6
BPC-157 and TB-500 for tendon tears
Why an online BPC-157 or TB-500 protocol cannot establish tendon healing when controlled human evidence and safety data are missing.
HD1916 trial: chemically made semaglutide
A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.
Multi-peptide stack safety: evidence limits
A forum list of peptide products cannot establish product quality, compatibility, or personal safety. Here is what an evidence-aware review requires.
Semaglutide care and weight-loss pressure
How to separate online weight-loss pressure from evidence, product labels, and an individualized conversation with a semaglutide prescriber.
Semaglutide constipation: safety boundaries
What current Wegovy labelling and trial evidence can say about constipation, plus the urgent-care boundary for serious digestive symptoms.
Buying Semaglutide Online: What to Verify
A source-based checklist for checking semaglutide telehealth marketing, compounded-drug status, FDA-approved labels, and pharmacy details.
Asthma Biologic Injection Pain
A multicenter observational study linked injection pain during severe-asthma biologic treatment with higher treatment-aversion scores.
Tirzepatide and kidney outcomes
A 2026 cohort study compared GLP-1/GIP therapies, including tirzepatide, with finerenone in type 2 diabetes and chronic kidney disease.
Tirzepatide and oral symptoms
A 2026 paper describes reported oral and salivary symptoms with incretin medicines, but it does not establish causation for tirzepatide.
Tirzepatide vs SGLT2 Drugs in MASLD
A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.
GIP Agonists and Blockers in Obesity
A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.
Can GLP-1 Drugs Make Botox Wear Off Sooner?
A computer model predicts shorter botulinum toxin A durability with GLP-1 drugs. It is a hypothesis, not proof from patient care.